New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10657910a.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 O,N

G2 C,H,Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:40:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   208927 TO ITERATE

100.0% PROCESSED   208927 ITERATIONS                              124 ANSWERS
SEARCH TIME: 00.00.05

L2          124 SEA SSS FUL L1

=> filecaplus
FILECAPLUS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   192.03     192.25

FILE 'CAPLUS' ENTERED AT 16:41:16 ON 18 OCT 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Oct 2010  VOL 153 ISS 17
FILE LAST UPDATED: 17 Oct 2010  (20101017/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l2
L3          12 L2
```

=> d 1-12 ibib abs hitstr
THE ESTIMATED COST FOR THIS REQUEST IS 69.72 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L3 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2010:555428 CAPLUS
DOCUMENT NUMBER: 153:134346
TITLE: Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III
AUTHOR(S): Shen, Yongchun; Boivin, Roch; Yoneda, Naoki; Du, Hong; Schiller, Shawn; Matsushima, Tomohiro; Goto, Masaki; Shirota, Hiroshi; Gusovsky, Fabian; Lemelin, Charles; Jiang, Yimin; Zhang, Zhiyi; Pelletier, Robert; Ikemori-Kawada, Megumi; Kawakami, Yoshiyuki; Inoue, Atsushi; Schnaderbeck, Matthew; Wang, Yuan
CORPORATE SOURCE: Eisai Inc., Andover, MA, 01810, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2010), 20(10), 3155-3157
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Inspired by natural product, LL-Z1640-2, clin. candidate, E6201 (22) was discovered in a medicinal chemical effort through total synthesis. The modification on C14-position to N-alkyl substitution showed to be potent in vitro and orally active in vivo in anti-inflammatory assays.
IT 603987-34-4P 603987-35-5P, E6201
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(discovery and preparation of potential antiinflammatory drug E6201)
RN 603987-34-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-35-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,

(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 603045-38-1 603045-40-5 1080810-70-3
1080810-73-6 1080810-74-7 1080810-93-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery and preparation of potential antiinflammatory drug E6201)
RN 603045-38-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-40-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-70-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-
[(phenylmethyl)amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-73-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(propylamino)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-74-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(diethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-93-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-amino-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 603045-46-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery and preparation of potential antiinflammatory drug E6201)
RN 603045-46-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2010:555406 CAPLUS
DOCUMENT NUMBER: 153:52939
TITLE: Discovery of an in vitro and in vivo potent resorcylic lactone analog of LL-Z1640-2 as anti-inflammatory lead, II
AUTHOR(S): Shen, Yongchun; Du, Hong; Kotake, Makoto; Matsushima, Tomohiro; Goto, Masaki; Shirota, Hiroshi; Gusovsky, Fabian; Li, Xiangyi; Jiang, Yimin; Schiller, Shawn; Spyvee, Mark; Davis, Heather; Zhang, Zhiyi; Pelletier, Robert; Ikemori-Kawada, Megumi; Kawakami, Yoshiyuki; Inoue, Atsushi; Wang, Yuan
CORPORATE SOURCE: Eisai Inc., Andover, MA, 01810, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2010), 20(10), 3047-3049
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The potent in vitro lead compound, ER-803064 (2), a MEK1 and MEKK1 inhibitor inspired from natural product LL-Z1640-2 (f152A1), was further optimized to improve in vitro and in vivo potency. The modifications on C14 position led to discovery of the lead compds. 28 and 29, which regained full in vitro potency of f152A1 and showed higher in vivo potency by iv administration.

IT 603045-46-1P 603985-63-3P 603985-64-4P
603985-65-5P 603985-70-2P 603985-71-3P
603985-72-4P 603985-78-0P 791101-15-0P
1080810-83-8P 1080811-06-8P 1080811-07-9P
1228924-58-0P 1228924-59-1P 1228924-60-4P
1228924-61-5P 1228924-62-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(resorcylic lactone analog of LL-Z1640-2 as anti-inflammatory lead)

RN 603045-46-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-63-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-64-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(2,3-dihydroxypropoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-65-5 CAPLUS
CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-70-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(4-morpholinyl)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-71-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-72-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-78-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 791101-15-0 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-[2-(dimethylamino)ethoxy]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-83-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-06-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-butoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-07-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(1-methylethoxy)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1228924-58-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-propoxy-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1228924-59-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(phenylmethoxy)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1228924-60-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-[(3,4-dichlorophenyl)methoxy]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1228924-61-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(2-
pyridinylamino)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1228924-62-6 CAPLUS
CN Acetamide, N-[2-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 603151-24-2 791101-13-8 1228924-57-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(resorcylic lactone analog of LL-Z1640-2 as anti-inflammatory lead)
RN 603151-24-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 791101-13-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1228924-57-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
13-bromo-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2010:50674 CAPLUS
DOCUMENT NUMBER: 152:177081
TITLE: Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of Ras/Raf/Mek pathway
INVENTOR(S): Garcia-Echeverria, Carlos; Maira, Sauveur-Michel; Stuart, Darrin; Wee, Susan; Fritsch, Christine; Nagel, Tobi
PATENT ASSIGNEE(S): Novartis A.-G., Switz.
SOURCE: PCT Int. Appl., 34pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010006225	A1	20100114	WO 2009-US50192	20090710

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2008-160218 A 20080711

AB The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a com. package or product comprising such a combination as a combined preparation for simultaneous, sep. or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.

IT 603987-35-5, E 6201
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of (a) phosphoinositide 3-kinase inhibitor and (b) modulator of Ras/Raf/Mek pathway)

RN 603987-35-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1364922 CAPLUS
DOCUMENT NUMBER: 152:66950
TITLE: E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9, 19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities
AUTHOR(S): Goto, Masaki; Chow, Jesse; Muramoto, Kenzo; Chiba, Ken-ichi; Yamamoto, Satoshi; Fujita, Masanori; Obaishi, Hiroshi; Tai, Kenji; Mizui, Yoshiharu; Tanaka, Isao; Young, Donna; Yang, Hua; Wang, Yuan J.; Shirota, Hiroshi; Gusovsky, Fabian
CORPORATE SOURCE: Eisai Tsukuba Research Laboratories, Ibaraki, Japan
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2009), 331(2), 485-495
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The goal of this study is to identify a novel inhibitor with anti-inflammatory and antiproliferative properties for the treatment of psoriasis. Compound f152A1 [(3S,5Z,8S,11E)-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-tetrahydro- 1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione] was identified as the main active metabolite with strong inhibitory activity against tumor necrosis factor-α (TNFα) transcription in a fraction originated from the fermentation broth of the fungus Curvularia verruculosa. Although active in cell-based assays, f152A1 was unstable in plasma and liver microsome prepns., thus limiting its pharmaceutical utilization. To improve the metabolic properties of f152A1, a medicinal chemical program was undertaken, resulting in the generation of over 400 analogs of f152A1. Eventually, E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9, 19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione] was identified as a promising analog in this series. In the present study, we

characterized the in vitro activities of E6201 and discovered that the compound inhibits lipopolysaccharide-activated TNFα reporter activity in THP-1-33 cells with an IC50 value of 50 nM and selectively inhibits mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1 in cell-free biochem. assays. In addition, E6201 showed inhibitory activity in several other cell-based systems:(1) phosphorylation of c-jun N-terminal kinase and p38 MAPKs; (2) nuclear factor-κB and activated protein-1 activation in various cell types; (3) interleukin (IL)-2 production from human lymphocytes; (4) hyperproliferation of human keratinocytes; (5) IL-8 production from human keratinocytes; and (6) proinflammatory cytokine production from human peripheral blood mononuclear cells. Based on the data presented here, E6201 may be beneficial for treatment of inflammatory and hyperproliferative diseases such as psoriasis through its anti-inflammatory activities on immune cells and antihyperproliferative activities on keratinocytes.

IT 603987-35-5, E 6201
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E6201 as possible treatment of inflammatory and hyperproliferative diseases such as psoriasis through anti-inflammatory activities on immune cells and antihyperproliferative activities in keratinocytes)

RN 603987-35-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1255859 CAPLUS
DOCUMENT NUMBER: 152:26048
TITLE: Discovery of a potent, metabolically stabilized resorcylic lactone as an anti-inflammatory lead
AUTHOR(S): Du, H.; Matsushima, T.; Spyvee, M.; Goto, M.; Shirota, H.; Gusovsky, F.; Chiba, K.; Kotake, M.; Yoneda, N.; Eguchi, Y.; DiPietro, L.; Harmange, J.-C.; Gilbert,

S.; Li, X.-Y.; Davis, H.; Jiang, Y.; Zhang, Z.; Pelletier, R.; Wong, N.; Sakurai, H.; Yang, H.; Ito-Igarashi, H.; Kimura, A.; Kuboi, Y.; Mizui, Y.; Tanaka, I.; Ikemori-Kawada, M.; Kawakami, Y.; Inoue, A.; Kawai, T.; Kishi, Y.; Wang, Y.
CORPORATE SOURCE: Eisai Research Institute of Boston, Andover, MA, 01810, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2009), 19(21), 6196-6199
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 152:26048
AB With bioactivity-guided phenotype screenings, a potent anti-inflammatory compound f152A1 has been isolated, characterized and identified as the known natural product LL-Z1640-2. Metabolic instability precluded its use for the study on animal disease models. Via total synthesis, a potent, metabolically stabilized analog ER-803064 has been created; addition of the (S)-Me group at C4 onto f152A1 has resulted in a dramatic improvement on its metabolic stability, while preserving the anti-inflammatory activities.

IT 603151-24-2P, ER 803064
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(potent, metabolically stabilized resorcylic lactone as an anti-inflammatory lead)

RN 603151-24-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 603959-45-1P 603959-46-2P 603987-75-3P
1080811-09-1P 1198575-05-1P 1198575-06-2P
1198575-07-3P 1198575-08-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(potent, metabolically stabilized resorcylic lactone as an

anti-inflammatory lead)
RN 603959-45-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-
, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603959-46-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-4-methyl-,
(4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-75-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-09-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1198575-05-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3R,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1198575-06-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
4-ethyl-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1198575-07-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-4,4-dimethyl-,
(5Z,8S,9S,11E)- (CA INDEX NAME)



RN 1198575-08-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-
(trifluoromethyl)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:741169 CAPLUS
DOCUMENT NUMBER: 151:78392
TITLE: Process for the preparation of intermediates toward the synthesis of zearalenone macrolide analogs
INVENTOR(S): Boivin, Roch; Campagna, Silvio A.; Du, Hong; Fang, Francis G.; Horstmann, Thomas; Lemelin, Charles-Andre; Li, Jing; McGuinness, Pamela; Niu, Xiang; Schnaderbeck, Matthew J.; Wu, Kevin; Zhu, Xiaojie
PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
SOURCE: PCT Int. Appl., 122pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009075818	A1	20090618	WO 2008-US13498	20081208
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2708141	A1	20090618	CA 2008-2708141	20081208
EP 2231635	A1	20100929	EP 2008-860534	20081208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
IN 2010KN01917	A	20100910	IN 2010-KN1917	20100526
MX 2010006091	A	20100625	MX 2010-6091	20100603

PRIORITY APPLN. INFO.:			
	US 2007-12408P	P	20071207
	US 2007-12409P	P	20071207
	US 2007-12411P	P	20071207
	US 2008-80048P	P	20080711
	WO 2008-US13498	W	20081208

OTHER SOURCE(S): MARPAT 151:78392
GI



I

AB A process for the preparation of zearalenone macrolide analogs intermediates, such as I, wherein R1 and R2 are independently H, alkyl, C1-6 unconjugated alkenyl and C3-6 unconjugated alkynyl groups; R3 is H or a base stable oxygen protecting group; R4 and R5 are independently H, halo,, alkyl, alkenyl, alkynyl, haloalkyl, Ph, benzyl, or taken together with the carbon atoms form a 5 or 6 membered unconjugated carbocyclic ring; R6 and R7 are independently H, or a base stable oxygen protecting group, or taken together to form a 5 membered heterocyclidyl moiety; and R8 is a (un)substituted Ph carbonyl moiety. The present intermediates are beneficial in that they provide purification points in the total synthesis, thus decreasing or removing the need for costly and time-consuming chromatog.

IT 603987-35-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(process for preparation of intermediates toward synthesis of zearalenone macrolide analogs)

RN 603987-35-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:741168 CAPLUS

DOCUMENT NUMBER: 151:78391
TITLE: Process for the preparation of intermediates toward the synthesis of zearalenone macrolide analogs
INVENTOR(S): Fang, Francis G.; Niu, Xiang; Schnaderbeck, Matthew J.
PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
SOURCE: PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2009075823	A1	20090618	WO 2008-US13512		20081208
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
CA 2708143	A1	20090618	CA 2008-2708143		20081208
EP 2231634	A1	20100929	EP 2008-860344		20081208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS					
MX 2010005999	A	20100623	MX 2010-5999		20100601
PRIORITY APPLN. INFO.:			US 2007-12408P	P	20071207
			US 2007-12409P	P	20071207
			US 2007-12411P	P	20071207
			US 2008-80048P	P	20080711
			WO 2008-US13512	W	20081208

OTHER SOURCE(S): MARPAT 151:78391
GI



I

AB A process for the preparation of zearalenone macrolide analogs intermediates, such as I, wherein R1 and R2 are independently H, alkyl, C1-6 unconjugated alkenyl and C3-6 unconjugated alkynyl groups; R3 is H or a base stable oxygen protecting group; R4 and R5 are independently H, halo,, alkyl, alkenyl, alkynyl, haloalkyl, Ph, benzyl, or taken together with the carbon atoms form a 5 or 6 membered unconjugated carbocyclic ring; R6 and R7 are independently H, or a base stable oxygen protecting group, or taken together to form a 5 membered heterocyclidyl moiety; and R8 is a (un)substituted Ph carbonyl moiety. The present intermediates are beneficial in that they provide purification points in the total synthesis, thus decreasing or removing the need for costly and time-consuming chromatog.

IT 603987-35-5P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparation of intermediates toward synthesis of zearalenone macrolide analogs)

RN 603987-35-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:547968 CAPLUS
DOCUMENT NUMBER: 150:506961
TITLE: Methods for prognosing the ability of a zearalenone analog compound to treat cancer
INVENTOR(S): Wang, John; Agoulnik, Sergei; Nomoto, Kenichi
PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
SOURCE: PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2009058908	A2	20090507	WO 2008-US81646	20081029
WO 2009058908	A3	20091022		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2008318690	A1	20090507	AU 2008-318690	20081029
CA 2704048	A1	20090507	CA 2008-2704048	20081029
US 20090170925	A1	20090702	US 2008-290405	20081029
EP 2215471	A2	20100811	EP 2008-845473	20081029
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				

PRIORITY APPLN. INFO.: US 2007-796P P 20071029
WO 2008-US81646 W 20081029

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The instant invention provides methods of prognosing the ability of a zearalenone analog compound to treat a cancer in a subject, methods of prognosing the ability of a zearalenone analog compound to inhibit the growth of a cancer in a subject, and methods of prognosing the ability of a zearalenone analog compound to promote the activation of apoptosis of a cancer in a subject. Methods of treating a cancer in a subject are also provided. The invention also pertains to methods of determining whether a cancer in a subject is sensitive to treatment with a zearalenone analog compound

IT 603987-34-4 603987-34-4D, esters
603987-35-5 603987-35-5D, esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for prognosing ability of zearalenone analog compound to treat cancer)

RN 603987-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-34-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-35-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-35-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:115045 CAPLUS
DOCUMENT NUMBER: 150:183364
TITLE: Multikinase inhibitors for use in the treatment of cancer
INVENTOR(S): Agoulnik, Sergei; Decosta, Bruce; Du, Hong; Jiang, Yimin; Li, Xiang-Yi; Nomoto, Kenichi; Wang, John; Zhang, Huiming
PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
SOURCE: PCT Int. Appl., 161pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009015368	A2	20090129	WO 2008-US71256	20080725
WO 2009015368	A3	20090326		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2008279027	A1	20090129	AU 2008-279027	20080725
CA 2698271	A1	20090129	CA 2008-2698271	20080725
US 20090082313	A1	20090326	US 2008-180408	20080725

KR 2010044868 A 20100430 KR 2010-7004170 20080725
EP 2182941 A2 20100512 EP 2008-796672 20080725
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS
CN 101778627 A 20100714 CN 2008-80023760 20100107
PRIORITY APPLN. INFO.: US 2007-951901P P 20070725
US 2007-951906P P 20070725
US 2008-29196P P 20080215
WO 2008-US71256 W 20080725
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 150:183364
AB The present invention provides Multikinase inhibitor compds., pharmaceutical compns. and methods for the treatment of specific cancers.
IT 603987-34-4P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(multikinase inhibitors for use in treatment of cancer)
RN 603987-34-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 603987-35-5P 1108192-75-1P 1108193-65-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(multikinase inhibitors for use in treatment of cancer)
RN 603987-35-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-75-1 CAPLUS
CN Carbamic acid, N-[2-[(2,3-dihydroxypropyl)amino]ethyl]-N-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 1108193-65-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-[(2,3-dihydroxypropyl)amino]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 603045-40-5P 603045-46-1P 1108192-70-6P
1108192-71-7P 1108192-72-8P 1108192-73-9P
1108192-76-2P 1108192-80-8P 1108193-01-6P
1108193-08-3P 1108193-12-9P 1108193-13-0P
1108193-14-1P 1108193-15-2P 1108193-21-0P
1108193-32-3P 1108193-41-4P 1108193-47-0P
1108193-73-2P 1108193-78-7P 1108193-97-0P
1108193-98-1P 1108193-99-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multikinase inhibitors for use in treatment of cancer)
RN 603045-40-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-46-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-70-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[[2-(1H-imidazol-1-yl)ethyl]amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-71-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[[2-(4-methyl-1-piperazinyl)ethyl]amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-72-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[[2-(4-morpholinyl)ethyl]amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-73-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[[2-(1-pyrrolidinyl)ethyl]amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-76-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-[[2-[(2,3-dihydroxypropyl)amino]ethyl]amino]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 1108192-80-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-01-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-methoxyethyl)amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-08-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(6,9,12-trioxa-3-azatridec-1-ylamino)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 1108193-12-9 CAPLUS
CN Acetamide, 2-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 1108193-13-0 CAPLUS
CN Acetamide, 2-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-14-1 CAPLUS
CN Acetamide, 2-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-15-2 CAPLUS
CN Glycine, N-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-21-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[[2-(phosphonooxy)ethyl]amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-32-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-[[(2R)-2,3-dihydroxypropoxy]amino]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-41-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(cyclopropylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-47-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 1108193-73-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[(4-piperidinylmethyl)amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-78-7 CAPLUS
CN Acetic acid, 2-[[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]amino]oxy]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-97-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5Z,8R,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-98-1 CAPLUS
CN Acetic acid, 2,2,2-trifluoro-, (3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-3,4,7,8,9,10-hexahydro-8,16-dihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-9-yl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 1108193-99-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



IT 603045-40-5D, ester derivs 603987-34-4D, ester
derivs 603987-35-5D, ester derivs 1108192-70-6D,
ester derivs 1108192-71-7D, ester derivs
1108192-72-8D, ester derivs 1108192-73-9D, ester
derivs 1108192-75-1D, ester derivs 1108192-76-2D,
ester derivs 1108192-80-8D, ester derivs
1108193-01-6D, ester derivs 1108193-08-3D, ester
derivs 1108193-12-9D, ester derivs 1108193-13-0D,
ester derivs 1108193-14-1D, ester derivs
1108193-15-2D, ester derivs 1108193-21-0D, ester
derivs 1108193-32-3D, ester derivs 1108193-41-4D,
ester derivs 1108193-65-2D, ester derivs
1108193-73-2D, ester derivs 1108193-78-7D, ester
derivs 1108193-97-0D, ester derivs 1108193-98-1D,
ester derivs 1108193-99-2D, ester derivs
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(multikinase inhibitors for use in treatment of cancer)
RN 603045-40-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-34-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-35-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-70-6 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[[2-(1H-imidazol-1-yl)ethyl]amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-71-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[[2-(4-methyl-1-piperazinyl)ethyl]amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-72-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[[2-(4-morpholinyl)ethyl]amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-73-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[[2-(1-pyrrolidinyl)ethyl]amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108192-75-1 CAPLUS
CN Carbamic acid, N-[2-[(2,3-dihydroxypropyl)amino]ethyl]-N-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

O

RN 1108192-76-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-[[2-[(2,3-dihydroxypropyl)amino]ethyl]amino]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

O

RN 1108192-80-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-01-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-methoxyethyl)amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-08-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(6,9,12-trioxa-3-azatridec-1-ylamino)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





RN 1108193-12-9 CAPLUS
CN Acetamide, 2-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-13-0 CAPLUS
CN Acetamide, 2-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-14-1 CAPLUS
CN Acetamide, 2-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-15-2 CAPLUS
CN Glycine, N-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-21-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[[2-(phosphonooxy)ethyl]amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-32-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-[[(2R)-2,3-dihydroxypropoxy]amino]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-41-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(cyclopropylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-65-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-[(2,3-dihydroxypropyl)amino]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-73-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[(4-piperidinylmethyl)amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-78-7 CAPLUS
CN Acetic acid, 2-[[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]amino]oxy]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-97-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,
(3S,4R,5Z,8R,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-98-1 CAPLUS
CN Acetic acid, 2,2,2-trifluoro-, (3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-
3,4,7,8,9,10-hexahydro-8,16-dihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-
benzoxacyclotetradecin-9-yl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 1108193-99-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



IT 1108193-20-9P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(multikinase inhibitors for use in treatment of cancer)
RN 1108193-20-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



IT 1108192-92-2P 1108193-00-5P 1108193-07-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(multikinase inhibitors for use in treatment of cancer)
RN 1108192-92-2 CAPLUS
CN Carbamic acid, N-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]-N-(2-hydroxyethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-00-5 CAPLUS
CN Carbamic acid, N-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]-N-(2-methoxyethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1108193-07-2 CAPLUS
CN 8,11,14-Trioxa-2,5-diazapentadecanoic acid, 5-[(1,1-dimethylethoxy)carbonyl]-2-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L3 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1487260 CAPLUS
DOCUMENT NUMBER: 150:35115
TITLE: Preparation of radicicol A analogs as kinase and phosphatase inhibitors
INVENTOR(S): Winssinger, Nicolas; Barluenga, Sofia
PATENT ASSIGNEE(S): Fr.
SOURCE: PCT Int. Appl., 124pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008149244	A2	20081211	WO 2008-IB2497	20080605
WO 2008149244	A3	20090312		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 2173733	A2	20100414	EP 2008-807156	20080605
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
US 20100233279	A1	20100916	US 2010-663079	20100524
PRIORITY APPLN. INFO.:			US 2007-933171P P	20070605
			WO 2008-IB2497 W	20080605

OTHER SOURCE(S): MARPAT 150:35115
GI



AB Radicicol A analogs of formula I [R1-R4, R7, R8 = H, halo, CN, OH, alkoxy, acyl, (substituted) NH2, alkylthio, aryl, etc.; R5, R6 = H, halo, CN, alkyl, aryl, etc.; R9-R11 = H, azide, OH, alkoxy, (substituted) NH2,

alkylthio, aryl, etc.; V = O, S, (substituted) NH; W = O, S (substituted) NH, etc.; X, Y = CH2, O, C, (substituted) NH, bond; XY = CH=CH, CHOH-CHOH, cyclopropadiyl, etc.; Z = (substituted) CH2, =CH, O, S, =N, bond, etc.] are prepared The compds. are kinase and phosphatase inhibitors and find utility in the treatment or prevention of kinase and phosphatase-mediated disorders. Also provided are uses and methods for the treatment or prevention of kinase- and phosphatase-mediated disorders and synthetic processes for the preparation of the compds. Thus, II was prepared, and was found to be a potent inhibitor of several kinases.

IT 1092507-26-0P 1092507-27-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of radicicol A analogs as kinase and phosphatase inhibitors)

RN 1092507-26-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 5-fluoro-3,4,9,10-tetrahydro-8,9,10,14,16-pentahydroxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,10S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1092507-27-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 5-fluoro-3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:964817 CAPLUS
DOCUMENT NUMBER: 141:410756
TITLE: Preparation of macrocyclic compounds for the treatment of inflammation and autoimmune disorders
INVENTOR(S): Chiba, Kenichi; Du, Hong; Eguchi, Yoshihito; Fujita, Masanori; Goto, Masaki; Gusovsky, Fabian; Harmange, Jean-Christophe; Inoue, Atsushi; Kawada, Megumi; Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura, Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Matsushima, Tomohiro; Mizui, Yoshiharu; Muramoto, Kenzo; Sakurai, Hideki; Shen, Yong-chun; Shirota, Hiroshi; Spyvee, Mark; Tanaka, Isao; Wang, John; Wood, Ray; Yamamoto, Satoshi; Yoneda, Naoki
PATENT ASSIGNEE(S): Japan
SOURCE: U.S. Pat. Appl. Publ., 299 pp., Cont.-in-part of Appl. No. PCT/US03/07377.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040224936	A1	20041111	US 2003-657910	20030909
WO 2003076424	A1	20030918	WO 2003-US7377	20030307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ZA 2004007156	A	20061227	ZA 2004-7156	20040907
WO 2005023792	A2	20050317	WO 2004-US29196	20040909
WO 2005023792	A3	20050623		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2008297317	A	20081211	JP 2008-194192	20080728

PRIORITY APPLN. INFO.:		
US 2002-362883P	P	20020308
US 2002-380711P	P	20020514
WO 2003-US7377	A2	20030307

JP 2003-574642 A3 20030307
US 2003-657910 A 20030909
OTHER SOURCE(S): CASREACT 141:410756; MARPAT 141:410756

GI



I



II

AB Macrocyclic compds. of formula I [R1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.; R2, R3 = H, halo, (substituted) OH, alkyl, aryl, etc.; R1R2, R1R3 = alkylene; R4 = H, halo; R5 = H, protecting group, prodrug; R6, R7, R11 = H, (substituted) OH; R8, R9 = H, halo, (substituted) OH, alkoxy, etc.; R10 = H, (substituted) OH, (substituted) NH2; n = 0-2; X = absent, O, NH, N-alkyl, CH2, S; Y, Z = CH, O, CO, NH, etc.] are prepared for the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis. In certain embodiments, methods for the treatment of various disorders including inflammatory or autoimmune disorders comprise systemically (e.g., orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. Thus, II was prepared in several steps. Some of the compds. inhibited NF-κB with IC50 values < 10μM.

IT 603039-45-8P 603045-38-1P 603045-40-5P
603045-42-7P 603045-44-9P 603045-46-1P
603151-24-2P 603151-32-2P 603151-34-4P
603959-45-1P 603985-37-1P 603985-63-3P
603985-65-5P 603985-69-9P 603985-71-3P
603985-72-4P 603985-73-5P 603985-74-6P
603985-75-7P 603985-77-9P 603985-78-0P
603986-04-5P 603987-34-4P 603987-35-5P
603987-75-3P 603987-93-5P 603988-36-9P
791101-13-8P 791101-14-9P 791101-15-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of macrocyclic compds. for the treatment of inflammatory or autoimmune disorders)

RN 603039-45-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(trifluoromethyl)-, (5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-38-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-40-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-42-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-
3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-44-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-
dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-46-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603151-24-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603151-32-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603151-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603959-45-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-
, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-37-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-63-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-65-5 CAPLUS
CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-69-9 CAPLUS

CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-71-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-72-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-73-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-74-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-75-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-ylmethyl)amino]ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

=O

RN 603985-77-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



=O

RN 603985-78-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603986-04-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2,2-
trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-34-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-35-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-75-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-93-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603988-36-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-dimethyl-, (3S,4R,5Z,8S,9R,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 791101-13-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 791101-14-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(methylamino)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 791101-15-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-[2-(dimethylamino)ethoxy]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

L3 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:737744 CAPLUS
DOCUMENT NUMBER: 139:261090
TITLE: Preparation of macrocyclic compounds for use in pharmaceutical and cosmetic compositions which regulate various genes involved in immune and inflammatory responses
INVENTOR(S): Boivin, Roch; Chiba, Kenichi; Davis, Heather A.; Diepitro, Lucian; Du, Hong; Eguchi, Yoshihito; Fujita, Masanori; Gilbert, Sandra; Goto, Masaki; Harmange, Jean Christophe; Inoue, Atsushi; Jiang, Yimin; Kawada, Megumi; Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura, Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Lemelin, Charles; Li, Xiang-yi; Matsushima, Tomohiro; Mizui, Yoshiharu; Sakurai, Hideki; Schiller, Shawn; Shen, Yongchun; Spyvee, Mark; Tanaka, Isao; Wang, Yuan; Yamamoto, Satoshi; Yoneda, Naoki; Kobayashi, Seiichi
PATENT ASSIGNEE(S): Eisai Co. Ltd., Japan; et al.
SOURCE: PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076424	A1	20030918	WO 2003-US7377	20030307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478065	A1	20030918	CA 2003-2478065	20030307
AU 2003224672	A1	20030922	AU 2003-224672	20030307
AU 2003224672	B2	20100204		
BR 2003008113	A	20050209	BR 2003-8113	20030307
EP 1507773	A1	20050223	EP 2003-721353	20030307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519954	T	20050707	JP 2003-574642	20030307
CN 1653059	A	20050810	CN 2003-810248	20030307
NZ 535101	A	20070727	NZ 2003-535101	20030307
RU 2334744	C2	20080927	RU 2004-129755	20030307
US 20040224936	A1	20041111	US 2003-657910	20030909
IN 2004KN01270	A	20060714	IN 2004-KN1270	20040830
IN 239297	A1	20100319		
ZA 2004007156	A	20061227	ZA 2004-7156	20040907
MX 2004008722	A	20050713	MX 2004-8722	20040908

NO 2004004256	A	20041207	NO 2004-4256		20041007
US 20060247448	A1	20061102	US 2004-507067		20041110
US 7799827	B2	20100921			
JP 2008297317	A	20081211	JP 2008-194192		20080728
AU 2010201776	A1	20100527	AU 2010-201776		20100504
PRIORITY APPLN. INFO.:			US 2002-362883P	P	20020308
			US 2002-380711P	P	20020514
			AU 2003-224672	A3	20030307
			JP 2003-574642	A3	20030307
			WO 2003-US7377	W	20030307

OTHER SOURCE(S): MARPAT 139:261090

GI



AB Macrocyclic lactones and lactams, such as I [R1 = H, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R2, R3 = H, OH, halogen, protected hydroxyl, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R1R2 or R1R3 = 3-8 membered alicyclic ring; R4 = H, halogen; R5 = H, hydroxyl protecting group, linked prodrug; R6, R7 = H, OH, protected hydroxyl; R8, R9, R10, R11 = H, OH, NH2, alkoxy, alkylamino, etc.; X = O, NH, S, CH2, etc.; R8R9 = fused ring, such as furan or imidazole; Y-Z = CH:CH, NHCO, etc.], were prepared for a variety of therapeutic and cosmetic uses, such as antitumor and anti-inflammatory agents and treatment of skin photodamage. These macrocycles are claimed for use as NF-κB, AP-1, protein kinase, cancer cell proliferation and solid tumor angiogenesis inhibitors and for use in the treatment of inflammation, cancer, psoriasis, skin photodamage, restenosis as stent coatings, rheumatoid arthritis, asthma, sepsis, inflammatory bowel

disease, atopic dermatitis, Crohn's disease, autoimmune disorders and for treatment of gastrointestinal, esophageal, tracheal/bronchial, urethral and vascular obstructions wherein the lumen of a body passageway is expanded. Thus, macrocyclic lactone II, designated as ER 803064, was prepared via a multistep synthetic sequence with included a macrolactonization reaction of III to form the desired lactone ring. The prepared macrocycles were assayed for their effect on TNF-α and β-actin placental alkaline phosphatase transcription using human acute monocytic leukemia cells.

IT 791101-13-8 1080810-60-1 1080810-61-2
1080810-62-3 1080810-64-5 1080810-65-6
1080810-66-7 1080810-68-9 1080810-70-3
1080810-71-4 1080810-72-5 1080810-73-6
1080810-74-7 1080810-75-8 1080810-76-9
1080810-77-0 1080810-78-1 1080810-79-2
1080810-80-5 1080810-81-6 1080810-82-7
1080810-83-8 1080810-84-9 1080810-85-0
1080810-86-1 1080810-87-2 1080810-88-3
1080810-89-4 1080810-90-7 1080810-91-8
1080810-92-9 1080810-93-0 1080810-95-2
1080810-96-3 1080810-97-4 1080810-98-5
1080810-99-6 1080811-01-3 1080811-02-4
1080811-03-5 1080811-04-6 1080811-05-7
1080811-06-8 1080811-07-9 1080811-08-0
1080811-09-1 1080811-10-4 1080811-11-5
1080811-12-6 1083006-06-7 1198575-07-3
RL: PRPH (Prophetic)
(Preparation of macrocyclic compounds for use in pharmaceutical and cosmetic compositions which regulate various genes involved in immune and inflammatory responses)

RN 791101-13-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-60-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-61-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-62-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-64-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Double bond geometry as shown.



RN 1080810-65-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-66-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-68-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-70-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-
[(phenylmethyl)amino]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-71-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-72-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 1080810-73-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(propylamino)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-74-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(diethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-75-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-76-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-77-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-78-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-79-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-80-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Double bond geometry as shown.



RN 1080810-81-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 1080810-82-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-83-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-84-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





RN 1080810-85-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-86-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-87-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 1080810-88-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 1080810-89-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-90-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 1080810-91-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-92-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-93-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-amino-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-95-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-96-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-97-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-98-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-99-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-01-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-02-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-03-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-04-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-05-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-06-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-butoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-07-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(1-methylethoxy)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-08-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-09-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-10-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 1080811-11-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-12-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1083006-06-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1198575-07-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-4,4-dimethyl-,
(5Z,8S,9S,11E)- (CA INDEX NAME)



IT 603044-46-8P 603045-38-1P 603045-40-5P
603045-42-7P 603045-44-9P, ER 807563
603045-45-0P 603045-46-1P 603151-24-2P, ER
803064 603151-32-2P 603151-34-4P, ER 804019
603959-46-2P, ER 804035 603985-37-1P
603985-63-3P 603985-64-4P 603985-65-5P
603985-69-9P 603985-70-2P, ER 804606
603985-72-4P 603985-73-5P 603985-74-6P
603985-75-7P 603985-76-8P 603985-77-9P
603985-78-0P 603986-04-5P, ER 804387
603987-34-4P 603987-35-5P 603987-75-3P
603987-93-5P, ER 806821 603988-36-9P
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of macrocyclic compds. for use in pharmaceutical and cosmetic compns. which regulate various genes involved in immune and inflammatory responses)
RN 603044-46-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5E,8R,9R,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-38-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-40-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-42-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-
3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-44-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-
dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-45-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-
[(methylsulfonyl)oxy]propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-46-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603151-24-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603151-34-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603959-46-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-4-methyl-,
(4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-37-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-63-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-64-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(2,3-dihydroxypropoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-65-5 CAPLUS
CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-69-9 CAPLUS
CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-70-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(4-morpholinyl)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-72-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-73-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-74-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-75-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-ylmethyl)amino]ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 603985-76-8 CAPLUS
CN Methanesulfonamide, N-[2-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-77-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 603985-78-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603986-04-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2,2-trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-34-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-35-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-75-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-93-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-
(methylamino)-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603988-36-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-
dimethyl-, (3S,4R,5Z,8S,9R,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 603039-45-8P 603959-45-1P 603985-71-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of macrocyclic compds. for use in pharmaceutical and cosmetic compns. which regulate various genes involved in immune and inflammatory responses)
RN 603039-45-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(trifluoromethyl)-, (5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603959-45-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-71-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT